Related Experiment Video
Updated: Apr 27, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
9.2K
The relationship between interleukin-18 polymorphisms and allergic disease: a meta-analysis
Daye Cheng1, Yiwen Hao1, Wenling Zhou1
1Department of Transfusion, The First Hospital of China Medical University, North Nanjing Street, No. 155, Shenyang, Liaoning 110001, China.
Biomed Research International
|July 5, 2014
Summary
Interleukin-18 (IL-18) gene polymorphisms IL-18 -607C/A and IL-18 -137G/C may offer protection against allergic asthma and dermatitis, respectively. This meta-analysis found these genetic variations are associated with a reduced risk of specific allergic conditions.
Area of Science:
- Genetics
- Immunology
- Allergy Research
Background:
- Previous studies suggested a link between IL-18 gene polymorphisms (-607C/A and -137G/C) and allergic disease risk, but findings were inconsistent.
- The role of these specific IL-18 polymorphisms in the development of various allergic conditions requires further clarification.
Purpose of the Study:
- To conduct a comprehensive meta-analysis evaluating the association between IL-18 -607C/A and -137G/C polymorphisms and the risk of allergic disease.
- To investigate potential associations within different ethnic groups, allergic disease types, and control sources.
Main Methods:
- A meta-analysis was performed, pooling data from 21 studies.
- Included were 5,331 cases and 9,658 controls investigating IL-18 -607C/A and -137G/C polymorphisms.
- Stratified analyses were conducted by ethnicity, allergic disease type, and control source.
Main Results:
- Overall and ethnicity-based analyses showed no significant association between IL-18 polymorphisms and general allergic disease risk.
- Stratified analysis revealed IL-18 -607C/A polymorphism was linked to a decreased risk of allergic asthma (heterozygous comparison).
- IL-18 -137G/C polymorphism was associated with a decreased risk of allergic dermatitis (recessive and homozygous comparisons).
- Further stratification indicated reduced risk for IL-18 -607C/A in population-based controls and for IL-18 -137G/C in hospital-based controls.
Conclusions:
- IL-18 -607C/A and -137G/C polymorphisms may act as protective factors against allergic asthma and allergic dermatitis, respectively.
- The specific associations appear dependent on the type of allergic disease and the source of control groups.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
29
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
29
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:28Asthma I: Introduction
88
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
88
01:26Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K